Transcriptional Repression of MiR-200 Family Members by Nanog in Colon Cancer Cells Induces Epithelial-mesenchymal Transition (EMT)
Overview
Authors
Affiliations
Nanog is an important embryonic stem cell (ESC) gene that does not function as a classical oncogene, but needs to cooperate with other molecules to potentiate tumorigenic activity. The question addressed by the present study was whether a miRNA link exists between Nanog and epithelial-mesenchymal transition (EMT)-mesenchymal-epithelial transition (MET) plasticity. Here, we found that Nanog mRNA expression level was inversely correlated with miR-200c and miR-200b expression levels in colon cancer cell lines and human colorectal cancer tissues. Forced Nanog expression in low-Nanog colon cancer cells inhibited miR-200c and miR-200b expression, and interfered Nanog expression in high-Nanog colon cancer cells promoted miR-200c and miR-200b expression. Furthermore, we confirmed that Nanog directly repressed transcription of the miR-200c and miR-200b genes, and miR-200c and miR-200b mediated Nanog-induced EMT occurrence. Luciferase and ChIP assays determined that Nanog bound directly to the potential Nanog binding sites in the miR-200c and miR-200b promoters and repressed their transcription. In conclusion, our findings suggest that Nanog modulates EMT-MET plasticity by regulating miR-200 clusters via a direct transcriptional mechanism, and the Nanog-miR-200 axis may be a good therapeutic target for CRC control.
MicroRNAs and colorectal cancer: clinical potential and regulatory networks.
Osei G, Adu-Amankwaah J, Koomson S, Beletaa S, Asiamah E, Smith-Togobo C Mol Biol Rep. 2023; 50(11):9575-9585.
PMID: 37776413 DOI: 10.1007/s11033-023-08810-w.
Zhang J, Shen Q, Xia L, Zhu X, Zhu X Front Oncol. 2022; 12:889238.
PMID: 35965516 PMC: 9372440. DOI: 10.3389/fonc.2022.889238.
Cavallari I, Ciccarese F, Sharova E, Urso L, Raimondi V, Silic-Benussi M Cancers (Basel). 2021; 13(23).
PMID: 34884985 PMC: 8656820. DOI: 10.3390/cancers13235874.
Chen X, Wang W, Li Y, Huo Y, Zhang H, Feng F J Exp Clin Cancer Res. 2021; 40(1):341.
PMID: 34706761 PMC: 8549173. DOI: 10.1186/s13046-021-02106-2.
Anastasiadou E, Ceccarelli S, Messina E, Gerini G, Megiorni F, Pontecorvi P PLoS One. 2021; 16(9):e0257070.
PMID: 34534238 PMC: 8448302. DOI: 10.1371/journal.pone.0257070.